GlobeNewsWire
29 Jun 2026, 20:30 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA has extended the PDUFA target action date for relutrigine by three months, from September 27, 2026, to December 27, 2026. — A delay in the approval timeline postpones potential commercial revenue and increases the burn rate for a biotech firm.
-0.40The FDA did not request any new clinical studies and cited no safety or manufacturing concerns regarding the relutrigine application. — The absence of requests for new trials or safety warnings mitigates the negative impact of the delay, suggesting the path to approval remains viable.
+0.30The FDA designated Praxis's submission of additional sensitivity analyses of existing clinical data as a 'major amendment.' — Major amendments typically trigger automatic review extensions and may signal that the FDA required more rigorous proof of efficacy.
-0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The FDA has extended the review period for relutrigine by three months, delaying the potential approval date.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Fox Business
23h ago
